Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 2

Treatment of systemic sclerosis: potential role for stem cell transplantation

Authors Xiong W, Derk C

Published 18 November 2009 Volume 2009:2 Pages 1—9

DOI https://doi.org/10.2147/SCCAA.S5282

Review by Single-blind

Peer reviewer comments 3

Wen Xiong, Chris T Derk

Division of Rheumatology, Thomas Jefferson University, Philadelphia, PA, 19107, USA

Abstract: Hematopoietic stem cell transplantation may “reset” the immune reconstitution and induce self tolerance of autoreactive lymphocytes, and has been explored in the treatments for systemic sclerosis. Phase I/II trials have shown a satisfactory risk benefit ratio. The true benefit will be identified by two ongoing prospective, randomized phase III trials. Multipotent mesenchymal stromal cells (MSCs) possess antiproliferative, anti-inflammatory, and immunosuppressive properties. The use of MSCs has showed successful responses in patients with severe steroid-resistant acute graft versus host disease in phase II trials, and may be a potentially promising option for patients with systemic sclerosis.

Keywords: scleroderma, systemic sclerosis, treatment, stem cells, transplant

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]